Abstract:<h3 class="Heading">Purpose</h3><p class="Para">Hepatocellular carcinoma (HCC) is a common cancer worldwide, and complete surgical resection of diseased tissue is a reliable strategy to cure cancer. Fluorescence image-guided surgery is a promising tool for surgeons to identify and remove malignant lesions. While non-targeted fluorescent dyes have been used for HCC diagnosis and resection, insufficient specificity and false positive uptake from inflammatory tissue result in a high recurrence rate or excessive excision of healthy liver tissue. To circumvent these problems, we focused on developing novel tumor-specific targeting probe to selectively illuminate cancer region during surgery. Given overexpression of histone deacetylases (HDACs) in HCC and many other cancers, HDAC-targeted imaging has been emerged as a promising tool for tumor detection.</p><h3 class="Heading">Procedures</h3><p class="Para">Recently, high expression of HDACs, in particular HDAC6, has been observed in tumor samples of HCC patient, and a few HDAC inhibitors, including FDA-approved suberoylanilide hydroxamic acid (SAHA), display potent antitumor effect on HCC. Correspondingly, in this study, we utilized a small molecule SAHA with the high HDAC-binding affinity as the HCC-specific targeting ligand to develop HDAC-targeted fluorescence probe for HCC detection and fluorescence image-guided resection.</p><h3 class="Heading">Results</h3><p class="Para">In <em class="EmphasisTypeItalic">in vitro</em> imaging, SAHA was labelled with fluorescein isothiocyanate (FITC) to evaluate targeting property, and the imaging results demonstrated that FITC-SAHA was specific uptake by HCC Bel-7402 cells. In <em class="EmphasisTypeItalic">in vivo</em> imaging, near infrared fluorescence dye IRDye800CW-labelled SAHA (NIR probe IRDye800CW-SAHA) showed rapid tumor accumulation with high tumor-to-background contrast on both the subcutaneous and orthotopic HCC mouse tumor models. Furthermore, the orthotopic HCC was successfully resected by the IRDye800CW-SAHA fluorescence image<strong class="EmphasisTypeBold">-</strong>guided surgery. Moreover, IRDye800CW-SAHA showed no toxicity toward healthy tissues.</p><h3 class="Heading">Conclusions</h3><p class="Para">Our results indicate that IRDye800CW-SAHA is a clinical translatable probe for HCC detection and resection.</p>

Recent advances in HDAC-targeted imaging probes for cancer detection

Molecular probing and imaging of histone deacetylase inhibitors in cancer treatment.

HDAC-targeting epigenetic modulators for cancer immunotherapy

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.

Technologies of Targeting Histone Deacetylase in Drug Discovery: Current Progress and Emerging Prospects.

New Development of HDAC Inhibitors As Anti-Cancer Agents

Advances in targeting histone deacetylase for treatment of solid tumors

Targeting histone deacetylases for cancer therapy: Trends and challenges

Discovery of non-substrate, environmentally sensitive turn-on fluorescent probes for imaging HDAC8 in tumor cells and tissue slices

Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

Environment-sensitive Fluorescent Inhibitors of Histone Deacetylase.

Progress of Hdac Inhibitor Panobinostat in the Treatment of Cancer

Selective histone deacetylase small molecule inhibitors: recent progress and perspectives

Histone Deacetylase (HDAC) Inhibitors in Cancer: a Patent Review (2017-Present)

The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

An Update On The Emerging Approaches For Histone Deacetylase (Hdac) Inhibitor Drug Discovery And Future Perspectives

An Activatable and Tumor-Targeting NIR Fluorescent Probe for Imaging of Histone Deacetylase 6 in Cancer Cells and in Vivo

Progress in clinical study of histone deacetylases inhibitors as anticancer agents

Strategies in Developing Promising Histone Deacetylase Inhibitors.